These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 29378238

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, Zha C, Ye Q, Jiang C, Cai J, Jiang T.
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M, Sareddy GR, Li M, Liu J, Luo Y, Venkata PP, Viswanadhapalli S, Tekmal RR, Brenner A, Vadlamudi RK.
    Sci Rep; 2019 Apr 16; 9(1):6124. PubMed ID: 30992459
    [Abstract] [Full Text] [Related]

  • 5. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG.
    Sci Transl Med; 2019 Feb 13; 11(479):. PubMed ID: 30760578
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG, Marand SV, Geraci S, Pycroft L, Berger FR, Pelletier LA.
    Oncotarget; 2015 Oct 06; 6(30):29456-68. PubMed ID: 26336131
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB.
    Aasland D, Götzinger L, Hauck L, Berte N, Meyer J, Effenberger M, Schneider S, Reuber EE, Roos WP, Tomicic MT, Kaina B, Christmann M.
    Cancer Res; 2019 Jan 01; 79(1):99-113. PubMed ID: 30361254
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
    Reich TR, Schwarzenbach C, Vilar JB, Unger S, Mühlhäusler F, Nikolova T, Poplawski A, Baymaz HI, Beli P, Christmann M, Tomicic MT.
    Cell Mol Life Sci; 2021 Jul 01; 78(14):5587-5604. PubMed ID: 34100981
    [Abstract] [Full Text] [Related]

  • 11. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
    Lu Y, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon SI, MacDonald J, Ewend MG, Gilbert MR, Yang C, Wu J.
    Cancer Res; 2017 Apr 01; 77(7):1709-1718. PubMed ID: 28202508
    [Abstract] [Full Text] [Related]

  • 12. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
    Bao Z, Chen L, Guo S.
    J Cell Biochem; 2019 Jun 01; 120(6):10205-10214. PubMed ID: 30592329
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death.
    He Y, Roos WP, Wu Q, Hofmann TG, Kaina B.
    Mol Cancer Res; 2019 May 01; 17(5):1129-1141. PubMed ID: 30796178
    [Abstract] [Full Text] [Related]

  • 16. Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.
    Lang F, Cornwell JA, Kaur K, Elmogazy O, Zhang W, Zhang M, Song H, Sun Z, Wu X, Aladjem MI, Aregger M, Cappell SD, Yang C.
    Neuro Oncol; 2024 Jun 03; 26(6):1083-1096. PubMed ID: 38134889
    [Abstract] [Full Text] [Related]

  • 17. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
    Zhang X, Yu J, Zhao C, Ren H, Yuan Z, Zhang B, Zhuang J, Wang J, Feng B.
    Biomed Pharmacother; 2019 Jan 03; 109():2192-2202. PubMed ID: 30551476
    [Abstract] [Full Text] [Related]

  • 18. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.
    Qin T, Mullan B, Ravindran R, Messinger D, Siada R, Cummings JR, Harris M, Muruganand A, Pyaram K, Miklja Z, Reiber M, Garcia T, Tran D, Danussi C, Brosnan-Cashman J, Pratt D, Zhao X, Rehemtulla A, Sartor MA, Venneti S, Meeker AK, Huse JT, Morgan MA, Lowenstein PR, Castro MG, Yadav VN, Koschmann C.
    Cell Rep; 2022 Jan 11; 38(2):110216. PubMed ID: 35021084
    [Abstract] [Full Text] [Related]

  • 19. Stalled replication forks within heterochromatin require ATRX for protection.
    Huh MS, Ivanochko D, Hashem LE, Curtin M, Delorme M, Goodall E, Yan K, Picketts DJ.
    Cell Death Dis; 2016 May 12; 7(5):e2220. PubMed ID: 27171262
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
    George SL, Lorenzi F, King D, Hartlieb S, Campbell J, Pemberton H, Toprak UH, Barker K, Tall J, da Costa BM, van den Boogaard ML, Dolman MEM, Molenaar JJ, Bryant HE, Westermann F, Lord CJ, Chesler L.
    EBioMedicine; 2020 Sep 12; 59():102971. PubMed ID: 32846370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.